Advertisement

Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery—a Prospective Clinical Study

  • Janelle D. VaughnsEmail author
  • Victoria C. Ziesenitz
  • Elaine F. Williams
  • Evan P. Nadler
  • Gerd Mikus
  • Johannes van den Anker
Original Contributions
  • 117 Downloads

Abstract

Introduction

Severe obesity predisposes youth to a higher risk of venous thromboembolism (VTE). This study evaluates a BMI-stratified prophylactic dosing regimen of enoxaparin in adolescents with severe obesity undergoing surgery.

Methods

Adolescents aged 12–20 years received prophylactic enoxaparin at 40 mg SC (for a BMI < 50 kg/m2) and 60 mg SC (for a BMI ≥ 50 kg/m2) every 12 h until discharge. Blood samples were drawn at pre-dose, 1, 2, 4, 6, and 12 h. Plasma Anti-Factor Xa (Anti-FXa) activity was used as a surrogate marker for enoxaparin pharmacokinetics.

Results

Ten female and two male obese adolescents (age range 14–19 years) had a mean BMI of 49.9 kg/m2 (38.4–58 kg/m2). Four patients had a BMI of less than 50 kg/m2 and received 40 mg enoxaparin, resulting in a mean dosage of 0.352 ± 0.070 mg/kg body weight. Eight patients were dosed with 60 mg enoxaparin every 12 h, resulting in a mean dosage of 0.395 ± 0.028 mg/kg. Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL. Median Tmax was 5.67 h (range 3.78–7.52 h). Median AUCi was 1.00 h IU/mL (range 0.42–1.67 h IU/mL). Ten out of 12 patients (83%) reached the primary endpoint with anti-FXa activity in the range for VTE prevention (0.1–0.3 IU/mL).

Conclusions

Our dosing scheme of 40 mg vs. 60 mg enoxaparin stratified according to BMI proved to be effective in reaching prophylactic anti-FXa activity in 83% of adolescent patients.

Keywords

Enoxaparin LMWH Obesity Adolescents Bariatric surgery VTE prophylaxis 

Notes

Funding Information

This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5T32HD087969) and with internal departmental funding.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Assent and Consent

Informed assent and consent was obtained from all individual participants and their parents in this study.

References

  1. 1.
    Skinner AC, Perrin EM, Moss LA, et al. Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med. 2015;373(14):1307–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Halvorson EE, Ervin SE, Russell TB, et al. Association of obesity and pediatric venous thromboembolism. Hosp Pediatr. 2016;6(1):22–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Raffini L, Huang YS, Witmer C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Carpenter SL, Richardson T, Hall M. Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014. Blood Adv. 2018;2(12):1403–8.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Stokes S, Breheny P, Radulescu A, et al. Impact of obesity on the risk of venous thromboembolism in an inpatient pediatric population. Pediatr Hematol Oncol. 2014;31(5):475–80.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Mahajerin A, Croteau SE. Epidemiology and risk assessment of pediatric venous thromboembolism. Front Pediatr. 2017;5:68.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Fareed J, Hoppensteadt D, Walenga J, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet. 2003;42(12):1043–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Brieger D, Dawes J. Long-term persistence of biological activity following administration of enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin. Thromb Haemost. 1996;75(5):740–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Wei MY, Ward SM. The Anti-Factor Xa range for low molecular weight heparin Thromboprophylaxis. Hematol Rep. 2015;7(4):5844.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Klaassen ILM, Sol JJ, Suijker MH, et al. Are low-molecular-weight heparins safe and effective in children? A systematic review. Blood Rev. 2019;33:33–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Mushtaq A, Vaughns JD, Ziesenitz VC, et al. Use of enoxaparin in obese adolescents during bariatric surgery--a pilot study. Obes Surg. 2015;25(10):1869–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Funk DM. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program. 2012;2012:460–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Lewis TV, Johnson PN, Nebbia AM, et al. Increased enoxaparin dosing is required for obese children. Pediatrics. 2011;127(3):e787–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898–909.CrossRefPubMedGoogle Scholar
  15. 15.
    Gelikas S, Eldar SM, Lahat G. Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. Surg Obes Relat Dis. 2017;13(10):1753–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tahaineh L, Edaily SM, Gharaibeh SF. Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. Clin Pharmacol. 2018;10:63–70.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Miranda S, Le Cam-Duchez V, Benichou J, et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: a comparative study of two regimens of enoxaparin: the ITOHENOX study. Thromb Res. 2017;155:1–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Anesthesiology, Pain and Perioperative MedicineChildren’s National Health System/The George Washington University School of Medicine and Health SciencesWashingtonUSA
  2. 2.Division of Pediatric Clinical PharmacologyChildren’s National Health System/The George Washington University School of Medicine and Health SciencesWashingtonUSA
  3. 3.Division of Pediatric Pharmacology & PharmacometricsUniversity of Basel Children’s HospitalBaselSwitzerland
  4. 4.Department of Pediatric and Congenital CardiologyUniversity Hospital HeidelbergHeidelbergGermany
  5. 5.Division of SurgeryChildren’s National Health System/The George Washington University School of Medicine and Health SciencesWashington DCUSA
  6. 6.Department of Clinical Pharmacology and PharmacoepidemiologyUniversity Hospital HeidelbergHeidelbergGermany

Personalised recommendations